InvestorsHub Logo
Followers 493
Posts 30550
Boards Moderated 3
Alias Born 01/31/2008

Re: None

Tuesday, 03/05/2024 7:23:25 AM

Tuesday, March 05, 2024 7:23:25 AM

Post# of 27839
BTTX .20 news out yesterday : Better Therapeutics Announces Acceptance of Late Breaking Abstract for Its AspyreRx Pivotal Trial 180 Day Outcomes and Participation at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)
Company to host sponsored education session on Saturday, March 09, 2024; Expanding access to a high quality and effective lifestyle modification intervention

SAN FRANCISCO--(BUSINESS WIRE)-- Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic diseases, today announced the acceptance of a late-breaking abstract presenting 180-day outcomes data and its participation at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD), to be held from March 6 to 9, 2024, in Florence, Italy. ATTD serves as a premier international forum showcasing cutting-edge advancements in diabetes care, bringing together clinicians, researchers, industry leaders, and policymakers from around the world to exchange knowledge and foster collaboration in the pursuit of innovative solutions for diabetes management.

All posts are my opinion and are not recommendations to buy or sell

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.